Placenta accrete spectrum. Placenta accreta
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group will receive 1 gram of intravenous tranexamic acid brand TRANEXIP® made by Caspian Tamin Pharmaceutical Company during 10 minutes immediately
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age over 18 years Diagnosis of placenta accrete spectrum syndrome on ultrasound Singleton pregnancy Cesarean section or cesarean section hysterectomy Patient consent to participate in the study
Exclusion criteria
Exclusion criteria: History of cardiovascular diseases including coronary artery disease, myocardial infarction, severe arrhythmias, and congestive heart failure history of the bleeding disorder including antiphospholipid syndrome (APS) liver and kidney disease known coagulation disorders anemia preoperatively (hemoglobin level < 8 mg/dl) history of preeclampsia or eclampsia in the current pregnancy contraindication to TXA use (history of TXA allergy, venous thromboembolism, active thrombolytic diseases, acquired color vision disorders, history of seizure, pre-known hematuria, and renal failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of estimated blood loss (EBL). Timepoint: Before and after surgery. Method of measurement: CC blood lost.;Complications during and after delivery. Timepoint: Evaluating the patient during and after delivery. Method of measurement: Incidence of complications during and after delivery such as rupture of the bowel, need for hysterectomy, hypogastric ligation, need for laparotomy, and rupture of the bladder. | — |
Secondary
| Measure | Time frame |
|---|---|
| Need to blood products transfusion. Timepoint: during the surgery and the first 24 h after delivery. Method of measurement: Amount of received PRBCs, amount of received platelets, and amount of received FFP.;Duration of hospitalization. Timepoint: Number of hospitalization days after delivery. Method of measurement: Number of hospitalization days. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKobra Shojaei
Ahvaz University of Medical Sciences
Outcome results
None listed